Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments

The pharmacological treatment of cognitive impairments associated with schizophrenia is still a major unmet clinical need. Indeed, treatments with available antipsychotics generate highly variable cognitive responses among patients with schizophrenia. This has led to the general assumption that anti...

Full description

Bibliographic Details
Main Authors: Sebastiano Alfio Torrisi, Samuele Laudani, Gabriella Contarini, Angelina De Luca, Federica Geraci, Francesca Managò, Francesco Papaleo, Salvatore Salomone, Filippo Drago, Gian Marco Leggio
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Pharmaceuticals
Subjects:
cognition
schizophrenia
dopamine receptors
second-generation antipsychotics
Online Access:https://www.mdpi.com/1424-8247/13/11/365

Internet

https://www.mdpi.com/1424-8247/13/11/365

Similar Items